EA201691641A1 - Химические соединения - Google Patents

Химические соединения

Info

Publication number
EA201691641A1
EA201691641A1 EA201691641A EA201691641A EA201691641A1 EA 201691641 A1 EA201691641 A1 EA 201691641A1 EA 201691641 A EA201691641 A EA 201691641A EA 201691641 A EA201691641 A EA 201691641A EA 201691641 A1 EA201691641 A1 EA 201691641A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
chemical compounds
enac
copd
asthma
Prior art date
Application number
EA201691641A
Other languages
English (en)
Other versions
EA029952B1 (ru
Inventor
Сусанн Элисабет Берглунд
Стивен Коннолли
Мартин Хеммерлинг
Нафизал Хоссаин
Анна КРИСТОФФЕРССОН
Йохан Руне Микаэль Лундквист
Григориос НИКИТИДИС
Лена Элисабет Рипа
Игорь ШАМОВСКИЙ
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201691641A1 publication Critical patent/EA201691641A1/ru
Publication of EA029952B1 publication Critical patent/EA029952B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Согласно настоящему изобретению предложено соединение формулы (I) или его фармацевтически приемлемая соль; способ получения такого соединения и применение такого соединение в лечении опосредуемого эпителиальными натриевыми каналами (ENaC) болезненного состояния (такого как астма, кистозный фиброз (CF) или хроническая обструктивная болезнь легких (COPD)).
EA201691641A 2014-03-18 2015-03-17 Химические соединения EA029952B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461954674P 2014-03-18 2014-03-18
PCT/GB2015/050765 WO2015140527A1 (en) 2014-03-18 2015-03-17 Chemical compounds

Publications (2)

Publication Number Publication Date
EA201691641A1 true EA201691641A1 (ru) 2017-02-28
EA029952B1 EA029952B1 (ru) 2018-06-29

Family

ID=52780553

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691641A EA029952B1 (ru) 2014-03-18 2015-03-17 Химические соединения

Country Status (38)

Country Link
US (3) US9873678B2 (ru)
EP (1) EP3119752B1 (ru)
JP (1) JP6502469B2 (ru)
KR (1) KR102296041B1 (ru)
CN (1) CN106103423B (ru)
AP (1) AP2016009447A0 (ru)
AR (1) AR099790A1 (ru)
AU (1) AU2015233195B2 (ru)
CA (1) CA2941807C (ru)
CL (1) CL2016002303A1 (ru)
CR (1) CR20160479A (ru)
CY (1) CY1120509T1 (ru)
DK (1) DK3119752T3 (ru)
DO (1) DOP2016000232A (ru)
EA (1) EA029952B1 (ru)
ES (1) ES2679618T3 (ru)
GT (1) GT201600190A (ru)
HR (1) HRP20181123T1 (ru)
HU (1) HUE039425T2 (ru)
IL (1) IL247610B (ru)
LT (1) LT3119752T (ru)
ME (1) ME03056B (ru)
MX (1) MX368577B (ru)
NI (1) NI201600134A (ru)
NZ (1) NZ724063A (ru)
PE (1) PE20170205A1 (ru)
PH (1) PH12016501808A1 (ru)
PL (1) PL3119752T3 (ru)
PT (1) PT3119752T (ru)
RS (1) RS57487B1 (ru)
SG (1) SG11201607751SA (ru)
SI (1) SI3119752T1 (ru)
SV (1) SV2016005278A (ru)
TR (1) TR201810207T4 (ru)
TW (1) TWI687410B (ru)
UY (1) UY36034A (ru)
WO (1) WO2015140527A1 (ru)
ZA (1) ZA201607136B (ru)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577418A (en) 1969-02-12 1971-05-04 Merck & Co Inc Pyrazinamide derivatives and processes for their preparation
US3573306A (en) 1969-03-05 1971-03-30 Merck & Co Inc Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides
FI820266L (fi) 1981-02-02 1982-08-03 Ici Plc Alkanolaminderivater
US4550111A (en) 1982-01-29 1985-10-29 Imperial Chemical Industries Plc Alkanolamine derivatives
GB8810933D0 (en) 1987-05-26 1988-06-15 Ici America Inc Heterocyclic compounds
GB8810934D0 (en) 1987-05-26 1988-06-15 Ici America Inc Amides
US4803206A (en) 1988-03-07 1989-02-07 Schering Corporation Antihypertensive acylpyrazines
GB8812342D0 (en) 1988-05-25 1988-06-29 Ici America Inc Bicyclic compounds
GB8812343D0 (en) 1988-05-25 1988-06-29 Ici America Inc Amino compounds
YU41399A (sh) 1997-02-26 2001-09-28 Pfizer Inc. Derivati amida heteroaril-kapronske kiseline, njihovo dobijanje i njihova upotreba kao selektivnih inhibitora mip-1.alfa vezivanjem za njegov ccr1 receptor
GB9930557D0 (en) 1999-12-23 2000-02-16 Rolic Ag Optically active materials
CA2408408C (en) 2000-05-12 2013-07-09 Genzyme Corporation Modulators of tnf- alpha signaling
EA200400648A1 (ru) 2001-11-08 2005-04-28 Элан Фармасьютикалз, Инк. N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040087571A1 (en) 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
MXPA05006679A (es) 2002-12-20 2005-08-16 Pfizer Prod Inc Inhibidores de la proteina de transferencia de trigliceridos microsomales.
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
EP1812378A2 (en) 2004-10-13 2007-08-01 University of Connecticut Cannabinergic lipid ligands
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
WO2009074575A2 (en) 2007-12-10 2009-06-18 Novartis Ag Organic compounds
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2723938A1 (en) 2008-05-13 2009-11-19 Novartis Ag 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
JP2011522860A (ja) * 2008-06-10 2011-08-04 ノバルティス アーゲー 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US9505735B2 (en) 2012-06-21 2016-11-29 Whitehead Institute For Biomedical Research Compounds for treating infectious diseases
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US9593084B2 (en) 2012-12-17 2017-03-14 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
WO2014099673A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds

Also Published As

Publication number Publication date
AP2016009447A0 (en) 2016-09-30
AR099790A1 (es) 2016-08-17
NI201600134A (es) 2017-03-13
ME03056B (me) 2018-10-20
EP3119752A1 (en) 2017-01-25
EP3119752B1 (en) 2018-05-16
SV2016005278A (es) 2016-11-30
AU2015233195B2 (en) 2017-04-20
AU2015233195A1 (en) 2016-09-22
DK3119752T3 (en) 2018-07-30
UY36034A (es) 2015-09-30
HRP20181123T1 (hr) 2018-09-21
CR20160479A (es) 2017-02-24
DOP2016000232A (es) 2016-10-16
SG11201607751SA (en) 2016-10-28
US10336725B2 (en) 2019-07-02
PH12016501808B1 (en) 2017-01-09
US9873678B2 (en) 2018-01-23
NZ724063A (en) 2018-02-23
SI3119752T1 (en) 2018-08-31
ZA201607136B (en) 2018-04-25
US20180162838A1 (en) 2018-06-14
PL3119752T3 (pl) 2018-09-28
RS57487B1 (sr) 2018-10-31
TWI687410B (zh) 2020-03-11
JP6502469B2 (ja) 2019-04-17
CN106103423A (zh) 2016-11-09
US10954211B2 (en) 2021-03-23
MX2016011681A (es) 2016-10-28
KR20160127135A (ko) 2016-11-02
PE20170205A1 (es) 2017-04-06
KR102296041B1 (ko) 2021-08-30
PH12016501808A1 (en) 2017-01-09
US20190330187A1 (en) 2019-10-31
JP2017512830A (ja) 2017-05-25
IL247610A0 (en) 2016-11-30
CN106103423B (zh) 2019-12-06
CA2941807C (en) 2023-03-07
LT3119752T (lt) 2018-08-10
EA029952B1 (ru) 2018-06-29
HUE039425T2 (hu) 2018-12-28
MX368577B (es) 2019-10-08
CY1120509T1 (el) 2019-07-10
CL2016002303A1 (es) 2017-01-13
PT3119752T (pt) 2018-07-24
TW201620880A (zh) 2016-06-16
CA2941807A1 (en) 2015-09-24
IL247610B (en) 2019-05-30
TR201810207T4 (tr) 2018-08-27
ES2679618T3 (es) 2018-08-29
US20170107195A1 (en) 2017-04-20
GT201600190A (es) 2019-07-29
WO2015140527A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
PH12018500088A1 (en) Substituted tricyclics and method of use
PH12017500797A1 (en) Substituted chromanes and methods of use
EA201790630A1 (ru) Способы получения рибозидов
NZ769042A (en) Compositions and methods for treating cns disorders
EA201691940A1 (ru) Новые соединения
GEP20186921B (en) Pyrazolopyridines and pyrazolopyrimidines
EA201591296A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
EA201490357A1 (ru) Индазолы
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA201692150A1 (ru) Способ лечения аденокарциномы легкого
EA201891143A1 (ru) Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
EA201891342A1 (ru) Изоиндольные соединения
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201891506A1 (ru) Индолиноновые соединения и их применение в лечении фиброзных заболеваний
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201892020A1 (ru) Индольные производные и их применение в качестве ингибиторов протеинкиназы
EA201690763A1 (ru) Лечение рака поджелудочной железы
NZ709199A (en) Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
EA201792234A1 (ru) Новые соединения пиридиния
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
EA201791689A1 (ru) Новые композиции и способы лечения и/или предупреждения хронического обструктивного заболевания легких
EA201691641A1 (ru) Химические соединения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM